Trial Profile

A Phase Ib Study of Ipatasertib, an AKT Inhibitor, in Combination With Pertuzumab Plus Trastuzumab in Patients With PI3KCA-mutant, HER2-positive Locally Advanced or Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipatasertib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions
Acronyms IPATHER

Most Recent Events

17 Apr 2023 Planned number of patients changed from 25 to 15.
17 Apr 2023 Planned End Date changed from 12 Aug 2024 to 25 Aug 2025.
17 Apr 2023 Planned primary completion date changed from 12 Feb 2023 to 25 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com